Senior Director, Country Manager, Austria
External
Revolution Medicines · Wien, ÖsterreichFull-timeOn-site1w ago
Prepare for this interview
EliteAI-generated questions, company research, and talking points tailored to this role
About the role
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) ...
Your Match
How well this role fits your profile.
Company Intel
What employees say
Worked at Revolution Medicines? Share your experience